Monday, August 29, 2016

Tuesday Features

Oramed hopes to start Phase 3 oral insulin trial next year

Oramed hopes to start Phase 3 oral insulin trial next year

Josh Hexter, COO & VP of Business Development After posting positive Phase 2b results with its oral insulin drug candidate, ORMD-0801 in Type 2 diabetes, Oramed Pharmaceuticals (NASDAQ:ORMP) hopes to meet with the FDA before the end of 2016 to discuss proceeding with a Phase 3 clinical trial in 2017. “We believe that our data set shows that oral... [Read more of this feature]


In conversation with Ben Haynor

In conversation with Ben Haynor

Senior Research Analyst, Ben Haynor As a senior research analyst with Feltl & Co. for the past six years, Ben Haynor ranked second in the May 2013 Wall Street Journal Best on the Street publication in the Medical Equipment and Supplies category and was named the top stock picker in U.S. Health Care Equipment and Supplies in StarMine’s 2013 analyst... [Read more of this feature]


Parvus developing Navacims to treat autoimmune diseases

Parvus developing Navacims to treat autoimmune diseases

CEO, Janice LeCocq Closely-held Parvus Therapeutics is developing a broad therapeutic platform, called Navacims, to treat autoimmune diseases through in vivo expansion and activation of disease-specific regulatory T-cells (T-regs), which normally play a key role in maintaining immune system balance and immune tolerance. “We have extensive preclinical... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Roth starts Actinium Pharma at buy

Roth starts Actinium Pharma at buy

Roth Capital Partners initiated coverage of Actinium Pharmaceuticals (NYSE MKT:ATNM) with a “buy” rating and $5 price target. The stock closed at $1.66 on Wednesday. “We believe it is an opportune time to explore the investment case of Actinium based on the late-stage nature of the lead asset, addressing unmet medical needs, clinical data in hand,... [Read more of this brief]


Analysts start Tactile Systems at buy, outperform

Analysts start Tactile Systems at buy, outperform

Analysts at BTIG Research, Piper Jaffray and William Blair initiated coverage of Tactile Systems Technology (NASDAQ:TCMD) with “buy,” “overweight” and “outperform” ratings, respectively. Tactile makes pneumatic compression devices (PCD) to treat lymphedema, along with a chronic venous leg ulcer product. Tactile closed an IPO of 4,120,000... [Read more of this brief]


IntelGenx has positive pilot study with montelukast film

IntelGenx has positive pilot study with montelukast film

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has completed a pilot clinical study for montelukast VersaFilm that demonstrated a significantly improved pharmacokinetic profile against the reference product. Montelukast is a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as mild cognitive impairment and Alzheimer’s... [Read more of this brief]


Leerink upgrades Cardiovascular Systems to outperform

Leerink upgrades Cardiovascular Systems to outperform

Leerink Partners upgraded Cardiovascular Systems (NASDAQ:CSII) to “outperform” and raised its price target to $30 from $23. The stock closed at $22.60 on Friday. “Now with two solid quarters in a row of stable-to-improving growth and a new CEO in place, we believe the company has reached a fundamental inflection point after several quarters of... [Read more of this brief]


WB starts 4 chronic Hep B biotechs at outperform

WB starts 4 chronic Hep B biotechs at outperform

William Blair initiated coverage at “outperform” of four biotech companies that are strategically positioned to benefit from the hepatitis B virus frontier. “Curing chronic hepatitis B infections is the next frontier after solving the hepatitis C problem, and the markets for both disease cures could be similar in size, reaching $200-billion each... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+